Susquehanna International Group
CTXR icon

Susquehanna International Group’s Citius Pharmaceuticals CTXR Stock Holding History

Susquehanna International Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,400
Closed -$29.3K – 12615
2025
Q2 		$29.3K Buy
+18,400
New +$16.9K ﹤0.01% 12255
2023
Q2 		– Sell
-1,428
Closed -$41.8K – 12210
2023
Q1 		$41.8K Buy
1,428
+484
+51% +$14K ﹤0.01% 11764
2022
Q4 		$18.6K Sell
944
-24
-2% -$655 ﹤0.01% 11786
2022
Q3 		$29K Buy
968
+148
+18% +$4.07K ﹤0.01% 12455
2022
Q2 		$19K Buy
820
+84
+11% +$2.3K ﹤0.01% 12374
2022
Q1 		$33K Sell
736
-1,976
-73% -$78K ﹤0.01% 12473
2021
Q4 		$104K Sell
2,712
-1,664
-38% -$75.5K ﹤0.01% 12120
2021
Q3 		$222K Buy
4,376
+3,164
+261% +$159K ﹤0.01% 11251
2021
Q2 		$105K Buy
+1,212
New +$72.8K ﹤0.01% 12072

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's CTXR Position: Q1 2026 in Review

Susquehanna International Group increased its Citius Pharmaceuticals (CTXR) stake by 186% in Q1 2026, buying an estimated $19.3K and bringing the position to 36,838 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #12743.

Susquehanna International Group first reported a position in CTXR in Q4 2019 and has held it in 20 quarters since. The position peaked at $721K in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Susquehanna International Group held 36,838 shares of Citius Pharmaceuticals worth $33.2K as of Q1 2026.
  • Susquehanna International Group bought 23,940 Citius Pharmaceuticals shares in Q1 2026, an estimated $19.3K.
  • Citius Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12743 holding.
  • Susquehanna International Group first reported a position in Citius Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Susquehanna International Group's Citius Pharmaceuticals position peaked at $721K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.